PMID: 11913478Mar 27, 2002Paper

Effects of trimetazidine on the contractile response of chronically dysfunctional myocardium to low-dose dobutamine in ischaemic cardiomyopathy

European Heart Journal
Romualdo Belardinelli, Augusto Purcaro

Abstract

There is evidence that trimetazidine, an anti-ischaemic agent with a direct cytoprotective effect on the myocardium, is effective in stable angina. However, it is not clear whether trimetazidine can improve the mechanical efficiency of chronically dysfunctional myocardium, and whether this potentially beneficial effect can translate into improvements in left ventricular function as well as functional capacity. Thirty-eight patients (52.7 +/- 8 years) with post-necrotic left ventricular dysfunction (ejection fraction: 33 +/- 5%) and multivessel coronary artery disease were studied. Patients were randomized into two matched groups. Group A received trimetazidine (20 mg three times daily) for 2 months, while group B received a placebo during the same period. The usual antianginal medications were not altered during the study. At baseline and after 2 months, all patients underwent low-dose dobutamine echocardiography (5-20 microg x kg(-1) x min(-1)), and a symptom-limited cardiopulmonary exercise test. On initial evaluation, systolic wall thickening score index, heart rate, systolic blood pressure and rate pressure product were similar at rest and peak dobutamine in both groups. However, at 2 months, group A patients had significan...Continue Reading

Citations

Apr 4, 2006·Heart Failure Reviews·Hani N Sabbah, William C Stanley
Jan 29, 2008·Current Heart Failure Reports·Gabriele FragassoAlberto Margonato
Jul 15, 2011·Diabetes Technology & Therapeutics·Sunil K KotaKirtikumar D Modi
Feb 4, 2011·Cardiovascular Research·Vincenzo LionettiFabio A Recchia
Mar 5, 2011·Cardiovascular Research·Helena Tuunanen, Juhani Knuuti
Apr 16, 2010·American Journal of Therapeutics·Chandrasekar PalaniswamyDiwakar Mohan
Mar 31, 2007·International Journal of Clinical Practice·G Fragasso
Jan 20, 2004·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Evgeniy V ShlyakhtoNatalya V Vakhrameyeva
Jun 30, 2005·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Taher El-KadySherif Abdel-Hady
Oct 2, 2009·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Shamanna S Iyengar, Giuseppe M C Rosano
Sep 1, 2009·Future Cardiology·Pericle Di Napoli, Alfonso A Taccardi
Jan 23, 2014·Heart·Elizabeth A DominicMadhumathi Rao
Jul 17, 2007·Canadian Journal of Physiology and Pharmacology·Arzu Onay-BesikciV Melih Altan
Apr 18, 2008·Current Cardiology Reports·Helena TuunanenJuhani Knuuti
May 9, 2002·Expert Opinion on Investigational Drugs·William C Stanley
Feb 19, 2010·Expert Opinion on Pharmacotherapy·Mohamed Amine ZaoualiJoan Roselló-Catafau
Nov 11, 2003·Current Medical Research and Opinion·Mario Marzilli
Feb 10, 2010·Scandinavian Cardiovascular Journal : SCJ·Torsten Doenst, Paulo A Amorim
Feb 3, 2016·Journal of Receptor and Signal Transduction Research·Ting ShiDianne M Perez
Dec 1, 2015·International Journal of Cardiology·Yuri M LopatinPiotr Ponikowski
Jul 8, 2008·Pharmacology & Therapeutics·Julian O M OrmerodMichael P Frenneaux
Apr 2, 2003·Fundamental & Clinical Pharmacology·William C Stanley, Mario Marzilli
Sep 14, 2006·Fundamental & Clinical Pharmacology·Eric E MorganWilliam C Stanley
Aug 26, 2006·The American Journal of Cardiology·Vicente Bertomeu-GonzalezJuan Carlos Kaski
Aug 26, 2006·The American Journal of Cardiology·Romualdo BelardinelliLoretta Volpe
Jun 12, 2003·European Journal of Heart Failure·Gavin I W Galasko, Avijit Lahiri
Oct 21, 2009·International Journal of Cardiology·Manish BansalThomas H Marwick
Jul 26, 2012·Journal of Molecular and Cellular Cardiology·Aaron K OlsonMichael A Portman
Mar 3, 2012·Journal of the American College of Cardiology·Lei ZhangJunbo Ge
Sep 5, 2006·Journal of the American College of Cardiology·Gabriele FragassoAlberto Margonato
Jun 4, 2004·Journal of Cardiovascular Pharmacology·Inga S ThrainsdottirLars Rydén

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.

Cardiology Journals

Discover the latest cardiology research in this collection of the top cardiology journals.

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.